Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT | Synapse
Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
Key Points
Key points are not available for this paper at this time.
Abstract
Preclinical data supporting the combination of DNA base excision repair inhibitor (TRC102) with DNA alkylating agent (TMZ)